CHAMAELEO PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
CHAMAELEO PHARMA
Largest movements
- Receivables within one year -€31,917
down €31,917 (-15.6%), from €203,989 to €172,072
- Other debts -€35,767
down €35,767 (-16.0%), from €223,169 to €187,402
- Profit (loss) carried forward +€3,630
up €3,630 (+1.4%), from -€262,689 to -€259,058
No income-statement line moved by more than 1% of the activity.
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €204,848 | €172,711 | -€32,137 | -15.7% |
| Fixed assets | 21/28 | €632 | €632 | = | 0.0% |
| Financial fixed assets | 28 | €632 | €632 | = | 0.0% |
| Current assets | 29/58 | €204,216 | €172,079 | -€32,137 | -15.7% |
| Amounts receivable within one year | 40/41 | €203,989 | €172,072 | -€31,917 | -15.6% |
| Other amounts receivable | 41 | €203,989 | €172,072 | -€31,917 | -15.6% |
| Cash at bank and in hand | 54/58 | €227 | €7 | -€220 | -96.7% |
| Total equity and liabilities | 10/49 | €204,848 | €172,711 | -€32,137 | -15.7% |
| Equity | 10/15 | -€19,123 | -€15,493 | +€3,630 | +19.0% |
| Contributions | 10/11 | €243,566 | €243,566 | = | 0.0% |
| Capital | 10 | €243,566 | €243,566 | = | 0.0% |
| Issued capital | 100 | €243,566 | €243,566 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€262,689 | -€259,058 | +€3,630 | +1.4% |
| Amounts payable | 17/49 | €223,971 | €188,204 | -€35,767 | -16.0% |
| Amounts payable within one year | 42/48 | €223,239 | €187,472 | -€35,767 | -16.0% |
| Trade debts | 44 | €70 | €70 | = | 0.0% |
| Suppliers | 440/4 | €70 | €70 | = | 0.0% |
| Other amounts payable | 47/48 | €223,169 | €187,402 | -€35,767 | -16.0% |
| Accrued charges and deferred income | 492/3 | €732 | €732 | = | 0.0% |
| Other operating charges | 640/8 | €675 | - | -€675 | |
| Operating profit (loss) | 9901 | -€675 | - | +€675 | |
| Financial charges | 65/66B | €74 | €20 | -€54 | -73.2% |
| Recurring financial charges | 65 | €74 | €20 | -€54 | -73.2% |
| Profit (loss) for the period before taxes | 9903 | -€748 | -€20 | +€729 | +97.4% |
| Profit (loss) for the period | 9904 | -€748 | -€20 | +€729 | +97.4% |
| Profit (loss) for the period to be appropriated | 9905 | -€748 | -€20 | +€729 | +97.4% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 23 October 2026 via checked.be.